

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: October 4, 2010

Signature: Lynn L. Janulis/53,066  
(Lynn L. Janulis)

Docket No.: 30572/42052  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Andreas Greinacher et al.

Application No.: 10/578,452

Confirmation No.: 2103

Filed: March 15, 2007

Art Unit: 1618

For: Use of MRP4-Inhibitors for the Treatment and/or  
Prophylaxis of Cardiovascular Diseases

Examiner: S. V. Gembeh

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the reference listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Applicant submits herewith a copy of non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Application No.: 10/578,452

Because this Supplemental Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits according to 37 CFR 1.97(c), Applicant submits herewith the \$180 fee set forth in 37 CFR 1.17(p).

No additional fee is believed to be due with the filing of this Supplemental Information Disclosure Statement. However, the Director is hereby authorized to charge any fee which should have been filed herewith (or with any paper hereafter filed in this application by this firm, except for the issue fee) to our Deposit Account No. 13-2855, under Order No. 30572/42052.

Dated: October 4, 2010

Respectfully submitted,

By /Lynn L. Janulis, #53,006/

Lynn L. Janulis

Registration No.: 53,066

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive

6300 Willis Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant